increase of policy interest rate. However, the Company has an appropriate capital management to optimize the efficiency of funding cost and the reduction of interest-bearing loans, along with liquidity
efficiency of funding cost, along with liquidity management. The average funding cost for the 9-month period of the year 2024 ended November 30, 2024 was 3.07%, increased from 2.99% at the end of last year
Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales
year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for
ongoing outbreak of COVID–19, forcing many customers to adjust their working method which have an effect on the operation and delivery of the Company's projects that cause the operation to be delayed than
reducing production cost and also negotiating with customers to review and adjust selling price every quarter. 2.2. Distribution costs for 2018 was in the amount of 4.95 million baht, increased by 1.16
with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
that the Company managed to properly slash sales expenses from the previous year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and